

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* venBio Global Strategic Fund II L.P. <hr/> (Last) (First) (Middle) 1700 OWENS STREET SUITE 595 <hr/> (Street) SAN FRANCISCO CA 94158 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Checkmate Pharmaceuticals, Inc. [CMPI]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 08/11/2020	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/11/2020		C		3,473,374	A	(1)(2)	3,473,374	D(3)	
Common Stock	08/11/2020		P		200,000	A	\$15	3,673,374	D(3)	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series A Preferred Stock	(1)	08/11/2020		C		12,500,000		(1)	(1)	Common Stock	1,671,771	\$0	0	D(3)	
Series B Preferred Stock	(2)	08/11/2020		C		8,753,350		(2)	(2)	Common Stock	1,314,165	\$0	0	D(3)	
Series C Preferred Stock	(1)	08/11/2020		C		3,644,624		(1)	(1)	Common Stock	487,438	\$0	0	D(3)	

1. Name and Address of Reporting Person*
[venBio Global Strategic Fund II L.P.](#)

 (Last) (First) (Middle)
 1700 OWENS STREET
 SUITE 595

 (Street)
 SAN FRANCISCO CA 94158

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
[venBio Global Strategic GP II, L.P.](#)

 (Last) (First) (Middle)
 1700 OWENS STREET
 SUITE 595

 (Street)
 SAN FRANCISCO CA 94158

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
[venBio Global Strategic GP II, Ltd.](#)

 (Last) (First) (Middle)

1700 OWENS STREET
SUITE 595

(Street)
SAN FRANCISCO CA 94158

(City) (State) (Zip)

1. Name and Address of Reporting Person*

GOODMAN COREY S

(Last) (First) (Middle)

1700 OWENS STREET
SUITE 595

(Street)
SAN FRANCISCO CA 94158

(City) (State) (Zip)

1. Name and Address of Reporting Person*

Adelman Robert J

(Last) (First) (Middle)

1700 OWENS STREET
SUITE 595

(Street)
SAN FRANCISCO CA 94158

(City) (State) (Zip)

Explanation of Responses:

1. The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
2. The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
3. The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.

venBio Global Strategic Fund II, L.P., by: venBio Global Strategic GP II, L.P., its general partner, by: venBio Global Strategic GP II, Ltd., its general partner, by: /s/ David Pezeshki, as attorney-in-fact 08/12/2020

venBio Global Strategic GP II, L.P., by: venBio Global Strategic GP II, Ltd., its general partner, by: /s/ David Pezeshki as attorney-in-fact 08/12/2020

venBio Global Strategic GP II, Ltd., by: /s/ David Pezeshki, as attorney-in-fact 08/12/2020

Corey Goodman, by: /s/ David Pezeshki, as attorney-in-fact 08/12/2020

Robert Adelman, by: /s/ David Pezeshki, as attorney-in-fact 08/12/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.